public entity
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
RAPT Therapeutics; public offering; common stock; underwritten offering; biopharmaceutical; immunology; market conditions; share dilution; offering pricing; gross proceeds
Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering
Praxis Precision Medicines; public offering; $525 million; stock offering; share offering; pricing; biopharmaceutical; central nervous system disorders
LB Pharmaceuticals Upsizes IPO to $285M, Marks First Major Biotech Listing in Months
LB Pharmaceuticals; IPO; biotech; $285 million; LBRX; schizophrenia; Phase III; public offering; Nasdaq; 2025 biotech IPOs
CNS Pharmaceuticals Pursues Public Offering to Fund Phase 2 GBM Trial After Cost Cuts
CNS Pharmaceuticals; biotech; layoffs; IPO; public offering; phase 2 trial; glioblastoma multiforme; funding; cash position
Senate Hearing for RFK Jr. Amid Strong Public Support for Vaccine Access
RFK Jr., Senate hearing, vaccine access, public support, FDA-approved vaccines, Department of Health and Human Services nomination
2024 Biotech IPOs: Insights and Trends
Biotech IPOs, 2024 IPO trends, biopharma sector, initial public offerings, venture capital investment, healthcare innovation.
Upstream Biotech Prepares to Join the Wave of Biotech IPOs with Inflammation-Focused Therapies
Biotech IPOs, Upstream Biotech, Inflammation-focused therapies, Biotechnology industry, Public offerings, Healthcare innovation
MBX Biosciences Enters IPO Queue Amid End-of-Summer Rush
MBX Biosciences, IPO, NASDAQ, peptide therapeutics, biotech, public offering
Alumis Secures $250 Million in Downsized Initial Public Offering
Alumis, Immunology Biotech, IPO, Initial Public Offering, Funding, Biotechnology